by David Porter
In his last message as ASTCT President, David Porter, MD, highlights how his successes in 2025 were a shared effort, made possible by the ASTCT Board, staff, and members. He reflects on key...
by Robert Korngold, PhD
This member spotlight features ex-officio ASTCT Board member Dr. Robert Korngold Ph.D., editor-in-chief for the Transplantation and Cellular Therapy journal. Korngold, a retired research scientist...
by Clinical Cancer Research
Chimeric antigen receptor (CAR) T-cell treatment has had limited success against pancreatic ductal adenocarcinoma (PDAC), but there is hope that incorporating ibrutinib or PD-1 blockade might...
by Journal of Clinical Investigation
Scientists developed a conditioning protocol that, followed by allogeneic bone marrow transplantation and islet transplantation, produces a favorable mix of host and donor hematopoietic stem cells...
by Blood
The results of a prospective study favor the use of a standardized protocol for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with a particular type of B-cell...
by Bone Marrow Transplantation
Donor traits and graft sources have a role in how outcomes play out after haploidentical hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL), report members of a...